Evidence map›Paper›PMID 24563633›Full record

ReviewTheScientificWorldJournal2014

Angiogenesis in spontaneous tumors and implications for comparative tumor biology.

C Benazzi, A Al-Dissi, C H Chau, W D Figg, G Sarli, J T de Oliveira, F Gärtner

Open access · goldAbstract readReview
In one paragraph

Review in TheScientificWorldJournal, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 48 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Review
  16. CD105 promotes hepatocarcinoma cell invasion and metastasis through VEGF.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2015
    Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 4 countries.

C BenazziDepartment of Veterinary Medical Sciences, University of Bologna, Via Tolara di Sopra 50, 40064 Ozzano Emilia, Bologna, Italy.
A Al-DissiDepartment of Veterinary Pathology, Western College of Veterinary Medicine, University of Saskatchewan, 52 Campus Drive, Saskatoon, SK, Canada S7N 5B4.
C H ChauNational Cancer Institute, Bethesda, MD 20892, USA.
W D FiggNational Cancer Institute, Bethesda, MD 20892, USA.
G SarliDepartment of Veterinary Medical Sciences, University of Bologna, Via Tolara di Sopra 50, 40064 Ozzano Emilia, Bologna, Italy.
J T de OliveiraInstitute of Pathology and Molecular Immunology of the University of Porto (IPATIMUP), 4200-456 Porto, Portugal ; Abel Salazar Institute of Biomedical Science, University of Porto (ICBAS-UP), 4200-456 Porto, Portugal.
F GärtnerInstitute of Pathology and Molecular Immunology of the University of Porto (IPATIMUP), 4200-456 Porto, Portugal ; Abel Salazar Institute of Biomedical Science, University of Porto (ICBAS-UP), 4200-456 Porto, Portugal.
National Cancer Institute · USUniversidade do Porto · PTUniversity of Bologna · ITUniversity of Saskatchewan · CA

Funding

Development of Anticancer AgentsZIASC006538 · NCI · DIVISION OF CLINICAL SCIENCES - NCI · PI FIGG, WILLIAM DOUGLAS · 2009 to 2025
$8.6M
6 · The paper itself

Abstract

Blood supply is essential for development and growth of tumors and angiogenesis is the fundamental process of new blood vessel formation from preexisting ones. Angiogenesis is a prognostic indicator for a variety of tumors, and it coincides with increased shedding of neoplastic cells into the circulation and metastasis. Several molecules such as cell surface receptors, growth factors, and enzymes are involved in this process. While antiangiogenic therapy for cancer has been proposed over 20 years ago, it has garnered much controversy in recent years within the scientific community. The complex relationships between the angiogenic signaling cascade and antiangiogenic substances have indicated the angiogenic pathway as a valid target for anticancer drug development and VEGF has become the primary antiangiogenic drug target. This review discusses the basic and clinical perspectives of angiogenesis highlighting the importance of comparative biology in understanding tumor angiogenesis and the integration of these model systems for future drug development.

Indexed as

Angiogenesis InhibitorsAnimalsDisease Models, AnimalDrug Evaluation, PreclinicalHumansNeoplasmsNeoplastic Stem CellsNeovascularization, PathologicSignal TransductionVascular Endothelial Growth Factor AAngiogenesis InhibitorsVascular Endothelial Growth Factor A

Identifiers

PMID24563633
PMCPMC3916025
OpenAlexW1972839104

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.